ProHealth health Vitamin and Natural Supplement Store and Health
Home  |  Log In  |  My Account  |  View Cart  View Your ProHealth Vitamin and Supplement Shopping Cart
800-366-6056  |  Contact Us  |  Help
Facebook Google Plus
Fibromyalgia  Chronic Fatigue Syndrome & M.E.  Lyme Disease  Natural Wellness  Supplement News  Forums  Our Story
Store     Brands   |   A-Z Index   |   Best Sellers   |   New Products   |   Deals & Specials   |   Under $10   |   SmartSavings Club

Trending News

Can Autoimmune Conditions be Reversed? Researchers Make a Surprising Discovery

How One Tiny Molecule Turned into One Huge Health Breakthrough

Nutrients Boost Stem Cell Function

Humans have three times more brown body fat

B12 Proven Essential for Every Cell

Soy isoflavones may benefit breast cancer patients

How B Vitamins Improve Brain Health, Cognition, Psychiatric Problems and Mood Disorders

Dietary prebiotics improve sleep, buffer impacts of stress, says study

Ylang Ylang Oil Not Only Soothes Your Skin, but Your Mind as Well

Exercises to Help Prevent Urinary Incontinence

 
Print Page
Email Article

Nightly treatment of primary insomnia with prolonged release melatonin for 6 months: A randomized placebo controlled trial on age and endogenous melatonin as predictors of efficacy and safety – Source: BMC Medicine, Aug 16, 2010

  [ 14 votes ]   [ Discuss This Article ]
By Alan G Wade, et al. • www.ProHealth.com • August 20, 2010


[Note: To read the full text of this article free, click HERE.]

Background: Melatonin [in regular and timed release form] is extensively used in the USA in a non-regulated manner for sleep disorders.

Prolonged release melatonin (PRM) is licensed in Europe and other countries for the short term treatment of primary insomnia in patients aged 55 years and over.

However, a clear definition of the target patient population and well-controlled studies of long-term efficacy and safety are lacking. It is known that melatonin production declines with age. Some young insomnia patients also may have low melatonin levels.

The study investigated:

• Whether older age or low melatonin excretion is a better predictor of response to PRM,

• Whether the efficacy observed in short-term studies is sustained during continued treatment,

• And the long term safety of such treatment.

Methods: Adult outpatients (791, aged 18-80 years) with primary insomnia, were treated with placebo (2 weeks) and then randomized, double-blind to 3 weeks with PRM or placebo nightly.

PRM patients continued whereas placebo completers were re-randomized 1:1 to PRM or placebo for 26 weeks with 2 weeks of single-blind placebo run-out.

Main outcome measures were sleep latency derived from a sleep diary, Pittsburgh Sleep Quality Index (PSQI), Quality of Life (World Health Organzaton-5) Clinical Global Impression of Improvement (CGI-I) and adverse effects and vital signs recorded at each visit.

Results:
On the primary efficacy variable sleep latency:

• The effects of PRM (3 weeks) in patients with low endogenous melatonin (6-sulphatoxymelatonin [6-SMT] 8 g/night) regardless of age did not differ from the placebo,

• Whereas PRM significantly reduced sleep latency compared to the placebo in elderly patients regardless of melatonin levels (-19.1 versus -1.7 min; P=0.002).

• The effects on sleep latency - and additional sleep and daytime parameters that improved with PRM - were maintained or enhanced over the 6-month period with no signs of tolerance.

Most adverse events were mild in severity with no clinically relevant differences between PRM and placebo for any safety outcome.

Conclusions:
• The results demonstrate short- and long-term efficacy and safety of PRM in elderly insomnia patients.

• Low melatonin production regardless of age is not useful in predicting responses to melatonin therapy in insomnia.

• The age cut-off for response warrants further investigation.

Source: BMC Medicine, Aug 16, 2010;8(1):51. PMID: 20712869, by Wade AG, Ford I, Crawford G, McConnachie A, Nir T, Laudon M, Zisapel N. CPS Research and Robertson Centre for Biostatistics, University of Glasgow, Glasgow, UK; Neurim Pharmaceuticals Ltd. and Department of Neurobiology, Faculty of Life Sciences, Tel Aviv University, Tel-Aviv, Israel. [Email: alangwade@fastmail.fm]





Post a Comment

Featured Products From the ProHealth Store
Melatonin Sublingual Tablets Vitamin D3 Extreme™ Ultra EPA  - Fish Oil

Looking for Vitamins, Herbs and Supplements?
Search the ProHealth Store for Hundreds of Natural Health Products


Article Comments



Be the first to comment on this article!

Post a Comment


 
NAD+ Ignite with Niagen

Featured Products

Ultra ATP+, Double Strength Ultra ATP+, Double Strength
Get energized with malic acid & magnesium
Melatonin Sublingual Tablets Melatonin Sublingual Tablets
Supports Deep, Restful Sleep Naturally
Ultra EPA  - Fish Oil Ultra EPA - Fish Oil
Ultra concentrated source of essential fish oils
FibroSleep™ FibroSleep™
The All-in-One Natural Sleep Aid

Natural Remedies

Live Without Anxiety or Stress Live Without Anxiety or Stress
How Glutathione Can Save Your Life How Glutathione Can Save Your Life
Restore Youthful Cognition and Well-Being Restore Youthful Cognition and Well-Being
Strengthen Cell Function with Energy-Boosting Niagen Strengthen Cell Function with Energy-Boosting Niagen
Quercetin: Natural Support for Allergy & Inflammation Relief and More Quercetin: Natural Support for Allergy & Inflammation Relief and More

CONTACT US
ProHealth, Inc.
555 Maple Ave
Carpinteria, CA 93013
(800) 366-6056  |  Email

· Become a Wholesaler
· Vendor Inquiries
· Affiliate Program
SHOP WITH CONFIDENCE
Credit Card Processing
SUBSCRIBE TO OUR NEWSLETTERS
Get the latest news about Fibromyalgia, M.E/Chronic Fatigue Syndrome, Lyme Disease and Natural Wellness

CONNECT WITH US ProHealth on Facebook  ProHealth on Twitter  ProHealth on Pinterest  ProHealth on Google Plus

© 2017 ProHealth, Inc. All rights reserved. Pain Tracker App  |  Store  |  Customer Service  |  Guarantee  |  Privacy  |  Contact Us  |  Library  |  RSS  |  Site Map